Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034069 (pulmonary fibrosis)
 7,050 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The activity of purified prolyl hydroxylase (proline, 2-oxoglutarate dioxygenase, EC 1. 14. 11. 2) was enhanced 3 approximately 8-fold at a low concentration of ferrous ion (1 X 10(-5 M) by addition of bleomycin, a glycopeptide antibiotic with antineoplastic activity and a side effect of producing pulmonary fibrosis. The maximum stimulation was attained at a concentration of 15 microgram/ml bleomycin (about 1 X 10(-5) M), which was approximately equimolar with the ferrous ion, one of the cofactors of this enzyme. Addition of bleomycin to the assay mixture resulted in a change of the optimal concentration of ferrous ion from 2 X 10(-3) M to 1 X 10(-5) M. Changing the order of addition of ferrous ion, enzyme and bleomycin in assay medium before incubation at 37 degrees C, the stimulatory activity was varied. Blemycin A2Cu++(Cu++-chelated bleomycin), which scarcely complexed with Fe++, had no enhancing effects on the enzymatic activity. We discuss the possible reasons as to why the activity of prolyl hydroxylase was enhanced by addition of bleomycin in the assay mixture.
J Antibiot (Tokyo) 1978 Sep
PMID:Stimulation of prolyl hydroxylase activity by bleomycin. 8 30

The literature suggests that 10% to 20% of adult patients with neurofibromatosis have associated interstitial lung disease. Characteristics of such involvement, as present in the case reported herein, include bilateral lower lobe fibrosis and may include bullous and cystic changes in advanced cases. In addition to pulmonary fibrosis, neurofibromatosis may have other intrathoracic associations; including "dumbbell" neurofibromas, intercostal neurofibromas, and intrathoracic meningoceles.
Arch Dermatol 1978 Sep
PMID:Neurofibromatosis and interstitial lung disease. 9 88

Two patients treated for acute leukaemia with BCNU, cyclophosphamide and cytosin-arabinoside are reported, in whom pulmonary fibrosis developed and progressed during therapy. The development of lung fibrosis during combined treatment, together with serological exclusion of other diseases known to be associated with pulmonary fibrosis, make a causal connection between the treatment and the fibrosis very probable.
Rofo 1978 Sep
PMID:[Progressive pulmonary fibrosis due to combined treatment with BCNU, cyclophosphospahmide and cytosin-arabinoside (author's transl)]. 15 Oct 43

The main purpose of our experimental series was to induce, in experimental animals, diffuse pulmonary fibrosis resembling that in human lungs. In the lungs of guinea-pigs injected with a soluble immune complex and continuously exposed to a 40-60 per cent oxygen-rich atmosphere, diffuse pulmonary fibrosis occurred in many cases in the course of 2 to 3 months after the injection. After the 100th experimental day, multiple foci of pulmonary adenomatosis occurred. The morphology was similar to that of Jaagsiekte. Electron microscopic observations revealed that these hyperplastic cells originated from type II pneumoncytes.
Acta Pathol Jpn 1975 Sep
PMID:Histopathological studies on experimentally induced pulmonary adenomatosis in guinea-pig lungs. 17 37

There are different patterns of development and resolution of inflammatory alveolar and interstitial pulmonary lesions. Delayed resolution of peripheral pneumonia results in lung shrinkage mainly towards the mediastinum and the apices with distortion and atypical distribution of pulmonary vasculature and compensatory hyperinflation. Resolution in perivascular and peribronchial parts is often delayed and results in scarring. Interstitial pneumonia may result directly in pulmonary fibrosis with loss of volume and honeycombing. With varying microorganisms and varying immunity chronic and atypical courses are observed more frequently.
Radiologe 1978 Sep
PMID:[Inflammatory pulmonary lesions: resolutions and residuals (author's transl)]. 30 40

A case of fatal pulmonary fibrosis and atypical epithelial proliferation (AEP) in a patient with multiple myeloma treated with melphalan is presented. Review of 10 other autopsied patients with myeloma treated with melphalan but no thoracic radiation, other cytotoxic agents, or highdose oxygen therapy revealed one other patient who died with extensive pulmonary fibrosis and AEP. Four other patients with AEP not associated with pneumonitis or fibrosis were also found, while no such changes were found in 11 autopsy controls or 11 patients with myeloma who did not receive cytotoxic agents. Melphalan should be added to the growing list of agents capable of causing severe fibrotic pulmonary reactions.
Cancer 1978 Sep
PMID:Pulmonary histopathologic changes associated with melphalan therapy. 35 22

"Continuous hemoperfusion" (8 h/day for 2--3 weeks) was performed in two patients suffering from severe paraquat intoxication. On account of paraquat plasma concentrations a fatal outcome due to pulmonary fibrosis would have been expected in both cases. However, both patients survived following "continuous hemoperfusion" therapy. Coated activated charcoal seems to have a higher affinity for paraquat than lung tissue.
Klin Wochenschr 1979 Sep 17
PMID:Two survivors of severe paraquat intoxication by "continuous hemoperfusion". 50 62

D-Penicillamine is used against a variety of diseases. For many years it has been successful in treating Wilson's disease, cystinuria and heavy-metal poisonings. It also proved to be effective against rheumatoid arthritis, scleroderma, chronic active hepatitis, pulmonary fibrosis and multiple sclerosis. However, the use of D-penicillamine is still limited owing to the frequent occurrence of considerable, though generally reversible, side effects. This article deals with the history of D-penicillamine as well as the methods of its synthesis, its pharmacokinetics, effects and side effects. In addition, the significance of the stereo isomeric L-penicillamine is discussed.
Naturwissenschaften 1979 Sep
PMID:[D-Penacillamine. From constituent of penicillins to significant drug]. 50 43

Although the carcinogenic properties of asbestos are presently attracting a good deal of attention, asbestosis is still the earliest lung disease resulting from exposure to it and its incidence in an exposed population is the most useful indicator of the degree of dust control exercised over a period of time. The diagnosis of asbestosis depends upon: (1) An adequate occupational exposure history. (2) Physical signs of pulmonary fibrosis. (3) Progressive radiological changes. (4) Confirmatory measurements of altered lung function. Asbestosis is a clinical entity and is readily diagnosed when all the above-mentioned criteria are met. Problems in diagnosis are encountered when one or more of the diagnostic criteria listed above cannot be substantiated. At the present time every effort is made to diagnose the disease in its early stages in the hope that removal from further exposure will prevent the direct and indirect complications.
J Occup Med 1977 Sep
PMID:Asbestosis -- a diagnostic enigma: a personal view. 59 91

Three patients developed diffuse pulmonary fibrosis caused by exposure to aerosolized cobalt while working in the tungsten carbide tool industry. Two cases were severe and one of these has died of cor pulmonale. The third is mildly disabled. The pathophysiology is reviewed. Clinicians and radiologists should be aware of hard metal exposure as a cause of diffuse interstitial fibrosis.
Radiology 1978 Sep
PMID:Hard metal pneumoconiosis: another cause of diffuse interstitial fibrosis. 67 25


1 2 3 4 5 6 7 8 9 10 Next >>